AS has become a significant management strategy for patients with low-risk PCa, with various eligibility criteria such as Gleason score (GS), PSA level, clinical stage, or percentage of disease on the biopsy cores [9]. The gene discussed is KLK3; the disease is posterior cortical atrophy.